Sugi Predict

Sugi Predict / Targets / B3GAT3

B3GAT3

Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3 · O94766 · B3GAT3 on Sugi Atlas →

77 patent compounds predicted against B3GAT3, 63 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL28984929 SCHEMBL28984929 1.00 1/20
SCHEMBL30267518 SCHEMBL30267518 1.00 1/20
SCHEMBL28984926 SCHEMBL28984926 0.88 1/20
SCHEMBL28984922 SCHEMBL28984922 0.85 1/20
SCHEMBL29504658 SCHEMBL29504658 0.81 1/20
SCHEMBL28984921 SCHEMBL28984921 0.79 1/20
SCHEMBL28984931 SCHEMBL28984931 0.79 1/20
SCHEMBL29504687 SCHEMBL29504687 0.79 1/20
SCHEMBL29504713 SCHEMBL29504713 0.79 1/20
SCHEMBL29504741 SCHEMBL29504741 0.79 1/20
SCHEMBL28984923 SCHEMBL28984923 0.78 1/20
SCHEMBL29504777 SCHEMBL29504777 0.76 1/20
SCHEMBL28984920 SCHEMBL28984920 0.75 1/20
SCHEMBL28984919 SCHEMBL28984919 0.75 1/20
SCHEMBL28985340 SCHEMBL28985340 0.74 1/20
SCHEMBL29234742 SCHEMBL29234742 0.65 1/20
SCHEMBL30267512 SCHEMBL30267512 0.65 1/20
SCHEMBL30267401 SCHEMBL30267401 0.65 1/20
SCHEMBL28985266 SCHEMBL28985266 0.64 1/20
SCHEMBL29234743 SCHEMBL29234743 0.63 1/20

Clinical trials — most relevant to B3GAT3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
A Safety and Efficacy Study of Fabrazyme® Replacement Therapy in Patients With Cardiac Fabry Disease PHASE4COMPLETED
A Study Evaluating Glycosphingolipid Clearance in Patients Treated With Agalsidase Alfa Who Switch to Agalsidase Beta PHASE4COMPLETED
A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms PHASE3COMPLETED
Vaccine Treatment for Surgically Resected Pancreatic Cancer PHASE1/PHASE2COMPLETED
A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis PHASE1/PHASE2RECRUITING
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer PHASE1/PHASE2COMPLETED
Study of Safety, Tolerability and Efficacy of PBGM01 in Pediatric Participants With GM1 Gangliosidosis PHASE1/PHASE2ACTIVE_NOT_RECRUITING
Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension PHASE2ACTIVE_NOT_RECRUITING
Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology PHASE2ACTIVE_NOT_RECRUITING
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG PHASE2COMPLETED
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients PHASE2ENROLLING_BY_INVITATION
A Study of GlcNAc on Tear Production in NGLY1-CDDG PHASE2ACTIVE_NOT_RECRUITING
A Study to Evaluate the Pharmacokinetics After Administration of BR3003 and Co-administration of BR3003B and BR3003C. PHASE1COMPLETED
Pharmacokinetics of BPDO-1603 or BPDO-16031 and BPDO-16033 Administration in Healthy Adults PHASE1COMPLETED
Glycosylation in Patients With Galactosaemia nanCOMPLETED
Inflammatory Pathways and Cardiac Growth Factors Associated With Fabry Disease Cardiomyopathy nanUNKNOWN
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation nanCOMPLETED
Evaluation of Gastrointestinal Symptoms Following Chilean Native Beans Consumption nanUNKNOWN
Canadian Fabry Disease Initiative (CFDI) National Registry nanRECRUITING
A Retrospective Study to Identify New Omics Biomarkers of Chronic/Persistent Low Back Pain nanCOMPLETED
Screening of Fabry Disease in Patients With GI Symptoms nanUNKNOWN
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease nanRECRUITING
Registry Gangliosidoses nanUNKNOWN
Oral Supplementation of Gangliosides to Treat a Rare Metabolic Disorder nanUNKNOWN
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes nanCOMPLETED
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) nanWITHDRAWN
Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease nanRECRUITING
Biomarker for Patients With Fabry Disease (BioFabry) nanWITHDRAWN
BMN 110 US Expanded Access Program nanAPPROVED_FOR_MARKETING
Institution of an Italian Multicenter Database of Patients Affected by Diseases of Phosphate Metabolism nanNOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a B3GAT3 binder may also engage these)

ProteinNameSimilarity
Q9WU47 — 1.000 Q9WU47 →
P58158 — 1.000 P58158 →
Q5CAZ6 — 0.993 Q5CAZ6 →
Q9P2W7 — 0.992 Q9P2W7 →
Q9CW73 — 0.991 Q9CW73 →
Q9NPZ5 — 0.990 Q9NPZ5 →
P59270 — 0.990 P59270 →
Q5CB03 — 0.990 Q5CB03 →
Q9Z137 — 0.986 Q9Z137 →
O60512 — 0.985 O60512 →
O35789 — 0.985 O35789 →
O97422 — 0.985 O97422 →
Q9BRR3 — 0.984 Q9BRR3 →
P15535 — 0.983 P15535 →
Q68FV3 — 0.983 Q68FV3 →
Q09200 — 0.983 Q09200 →
Q91YY2 — 0.983 Q91YY2 →
Q6P768 — 0.983 Q6P768 →
A0A4Z3 — 0.983 A0A4Z3 →
O75064 — 0.983 O75064 →
Q01634 — 0.982 Q01634 →
Q5NVN3 — 0.982 Q5NVN3 →
Q8S626 — 0.982 Q8S626 →
Q80WN9 — 0.982 Q80WN9 →
Q5CB04 — 0.982 Q5CB04 →
Q5EA87 — 0.982 Q5EA87 →
Q8IXK2 — 0.981 Q8IXK2 →
Q3V1N9 — 0.981 Q3V1N9 →
Q13724 — 0.981 Q13724 →
Q495W5 — 0.980 Q495W5 →